The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC).
 
Belen Caramelo
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Nerea Muñoz Unceta
No Relationships to Disclose
 
Javier Freire
No Relationships to Disclose
 
Ignacio Varela
No Relationships to Disclose
 
David Martin
No Relationships to Disclose
 
Sofía Del Carmen
No Relationships to Disclose
 
Ainara Azueta
No Relationships to Disclose
 
Pilar Diaz
No Relationships to Disclose
 
Pilar Garcia-Berbel
No Relationships to Disclose
 
Naiara Sagastibelza Marinelarena
Honoraria - Bristol-Myers Squibb; MSD Oncology
Travel, Accommodations, Expenses - Merck; Roche
 
Macarena Rey-Cárdenas
No Relationships to Disclose
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Miguel Ángel Climent
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai Europe; EUSA Pharma; Ipsen; Janssen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Eisai; EUSA Pharma; Janssen Oncology; Janssen-Cilag; Merck; MSD Oncology; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen; Merck; Pfizer; Roche
 
Javier Puente
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer; Roche
 
Juan Irure
No Relationships to Disclose
 
Laura Revuelta
No Relationships to Disclose
 
Fernanda Genre
No Relationships to Disclose
 
Diego Cacho
No Relationships to Disclose
 
Javier Gómez
No Relationships to Disclose
 
Ignacio Duran
Honoraria - Astellas Pharma; AstraZeneca Spain; Bayer/Onyx; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Immunomedics; Janssen Oncology; MSD Oncology; Novartis; Pfizer/EMD Serono; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer; Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca Spain; Bayer/Onyx; Gilead Sciences; Ipsen; Pfizer/EMD Serono; Roche/Genentech